Edgewise Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $12.17M, a 438.39% increase year-over-year.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $2.26M, a 17.39% increase year-over-year.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $3.55M, a 118133.33% increase year-over-year.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $1.93M, a 9071.43% increase year-over-year.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $117.00K, a 71.11% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $405.00K, a 249.14% increase from fiscal 2021.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $116.00K, a 42.57% decline from fiscal 2020.
- Edgewise Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $202.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $12.17M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $2.26M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $3.55M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $1.93M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $117.00K 10-K · filed 2024-02-22 | |
| 2023-09-30 | $3.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $21.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $405.00K 10-K · filed 2024-02-22 | |
| 2022-09-30 | $52.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $255.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $73.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $116.00K 10-K · filed 2023-02-23 | |
| 2021-09-30 | $37.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $5.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $25.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $202.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $67.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $120.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $15.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |